retatrutide peptide clinical trials Today, we shared new data from two Phase 3 of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Triple hormone receptor agonist retatrutide

Although converting to GLP-1 agonists is valuable for personalized treatment, you will need to consult a healthcare provider experienced in GLP-1 medications for careful planning and continuous monitoring

[1] [2] It belongs to a novel class of drugs known as triple receptor agonists, distinguishing it from earlier-generation weight-loss medications

Symptoms are often most noticeable during treatment initiation or dose escalation

The study was sponsored by Eli Lilly and Company, the manufacturer of orforglipron and the injectable GLP-1 tirzepatide

Your labs go straight to our medical team for review, at no charge, and the review happens before your first visit

Start the dietary elimination phase (remove eggs, cruciferous vegetables, garlic, onions, carbonated drinks, sugar-free gum)